Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 88 results for pulmonary hypertension

  1. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

  2. Percutaneous balloon valvuloplasty for fetal critical aortic stenosis (IPG613)

    Evidence-based recommendations on percutaneous balloon valvuloplasty for fetal critical aortic stenosis. This involves placing a catheter into the baby’s heart, while the baby is still in the womb. The aim is to help the heart develop properly.

  3. Acute kidney injury: prevention, detection and management (NG148)

    This guideline covers preventing, detecting and managing acute kidney injury in children, young people and adults. It aims to improve assessment and detection by non-specialists, and specifies when people should be referred to specialist services. This will improve early recognition and treatment, and reduce the risk of complications in people with acute kidney injury.

  4. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

  5. Neonatal infection (QS75)

    This quality standard covers preventing bacterial infection in newborn babies, treating pregnant women and pregnant people whose babies are at risk of infection, and treating newborn babies with suspected or confirmed bacterial infection. It includes when to give antibiotics to prevent and treat neonatal bacterial infection and describes high-quality care in priority areas for improvement. This includes early-onset (within 72 hours of birth) and late-onset (between 72 hours and 28 days following birth) neonatal infection.

  6. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.

  7. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

  8. Research recommendations

    CG121/3 | Pulmonary rehabilitation, optimisation of drug treatment and enhanced recovery programmes:-

  9. Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274)

    Evidence-based recommendations on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. This involves removing parts of the pancreas (islet cells) after the pancreas has been removed and inserting them into the liver to restart insulin production.

  10. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

    Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.

  11. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

  12. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.

  13. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

  14. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.